EBV Chronic Infections

Pizzigallo Eligio, Racciatti Delia, Gorgoretti Valeria, Pizzigallo Eligio, Racciatti Delia, Gorgoretti Valeria

Abstract

The infection from Epstein-Barr virus (EBV) or virus of infectious mononucleosis, together with other herpes viruses' infections, represents a prototype of persistent viral infections characterized by the property of the latency. Although the reactivations of the latent infection are associated with the resumption of the viral replication and eventually with the "shedding", it is still not clear if this virus can determine chronic infectious diseases, more or less evolutive. These diseases could include some pathological conditions actually defined as "idiopathic"and characterized by the "viral persistence" as the more credible pathogenetic factor. Among the so-called idiopathic syndromes, the "chronic fatigue syndrome" (CFS) aroused a great interest around the eighties of the last century when, just for its relationship with EBV, it was called "chronic mononucleosis" or "chronic EBV infection".Today CFS, as defined in 1994 by the CDC of Atlanta (USA), really represents a multifactorial syndrome characterized by a chronic course, where reactivation and remission phases alternate, and by a good prognosis. The etiopathogenetic role of EBV is demonstrated only in a well-examined subgroup of patients, while in most of the remaining cases this role should be played by other infectious agents - able to remain in a latent or persistent way in the host - or even by not infectious agents (toxic, neuroendocrine, methabolic, etc.). However, the pathogenetic substrate of the different etiologic forms seems to be the same, much probably represented by the oxidative damage due to the release of pro-inflammatory cytokines as a response to the triggering event (infectious or not infectious).Anyway, recently the scientists turned their's attention to the genetic predisposition of the subjects affected by the syndrome, so that in the last years the genetic studies, together with those of molecular biology, received a great impulse. Thanks to both these studies it was possibile to confirm the etiologic links between the syndrome and EBV or other herpesviruses or other persistent infectious agents.The mechanisms of EBV latency have been carefully examined both because they represent the virus strategy to elude the response of the immune system of the host, and because they are correlated with those oncologic conditions associated to the viral persistence, particularly lymphomas and lymphoproliferative disorders. Just these malignancies, for which a pathogenetic role of EBV is clearly documented, should represent the main clinical expression of a first group of chronic EBV infections characterized by a natural history where the neoplastic event aroused from the viral persistence in the resting B cells for all the life, from the genetic predisposition of the host and from the oncogenic potentialities of the virus that chronically persists and incurs reactivations.Really, these oncological diseases should be considered more complications than chronic forms of the illness, as well as other malignancies for which a viral - or even infectious - etiology is well recognized. The chronic diseases, in fact, should be linked in a pathogenetic and temporal way to the acute infection, from whom start the natural history of the following disease. So, as for the chronic liver diseases from HBV and HCV, it was conied the acronym of CAEBV (Chronic Active EBV infection), distinguishing within these pathologies the more severe forms (SCAEBV) mostly reported in Far East and among children or adolescents. Probably only these forms have to be considered expressions of a chronic EBV infection "sensu scrictu", together with those forms of CFS where the etiopathogenetic and temporal link with the acute EBV infection is well documented. As for CFS, also for CAEBV the criteria for a case definition were defined, even on the basis of serological and virological findings. However, the lymphoproliferative disorders are excluded from these forms and mantain their nosographic (e.g. T or B cell or NK type lymphomas) and pathogenetic collocation, even when they occur within chronic forms of EBV infection. In the pathogenesis, near to the programs of latency of the virus, the genetic and environmental factors, independent from the real natural history of EBV infection, play a crucial role.Finally, it was realized a review of cases - not much numerous in literature - of chronic EBV infection associated to chronic liver and neurological diseases, where the modern techniques of molecular biology should be useful to obtain a more exact etiologic definition, not always possibile to reach in the past.The wide variety of clinical forms associated to the EBV chronic infection makes difficult the finding of a univocal pathogenetic link. There is no doubt, however, that a careful examination of the different clinical forms described in this review should be useful to open new horizons to the study of the persistent viral infections and the still not well cleared pathologies that they can induce in the human host.

Figures

Figure 1.
Figure 1.
Classification of fatigue (Fukuda et al 68).
Figure 2.
Figure 2.
CFS: Pathogenesis

References

    1. Southern P, Oldstone MBA. Medical consequences of persistent viral infection. N Engl J Med. 1986;314:359–67.
    1. Haywood AM. Patterns of persistent viral infections. N Engl J Med. 1986;315:939–48.
    1. Behan PO, Behan WMH. Postviral fatigue syndrome. CRC Crit Rev Neurobiol. 1988:157–78.
    1. Miyashita EM, Thorley-Lawson DA. EBV: persistence and disease. Giorn It Mal Inf. 1996;2:133–6.
    1. Moroni M. Il concetto di guarigione nelle malattie infettive. Giorn It Mal Inf. 2006;12:26–8.
    1. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and origins of associated lymphomas. N Engl J Med. 2004;350:1328–36.
    1. Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci. 2001;336:461–73.
    1. Kieff E. BN Fields and DH Knipe, eds Field’s virology. 3rd ed. New York: Lippincott-Raven; 1996. Epstein-Barr virus and its replication; pp. 2243–69.
    1. Fingeroth JD, Clabby ML, Strominger JD. Characterization of a T-lymphocyte Epstein-Barr virus C3d receptor (CD21) J Virol. 1988;62:1442–7.
    1. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med. 1984;310:1225–30.
    1. Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B, Hutt-Fletcher LM. Epstein-Barr virus uses HLA Class II as a cofactor for infection of B lymphocytes. J Virol. 1997;71:4657–62.
    1. Hochberg D, Souza J, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cells compartment with resting, latently infected cells. J Virol. 2004;78:5194–204.
    1. Choen JL. Epstein-Barr virus infection. N Engl J Med. 2000;343:480–92.
    1. Anagnostopoulos I, Hummel M, Kreshel C, Stein H. Morphology, immunophenotype and distribution of latently end/or productively Epstein-Barr virus infected cells in acute infecious mononucleosis: implications for the interdividual infection route of Epstein-Barr virus. Blood. 1995;85:744–50.
    1. Straus SE, Cohen JI, Tosato G, Meier J. Epstein-Barr virus infections: biology, pathogenesis and management. Ann Int Med. 1993;118:45–58.
    1. Foss HD, Herbst H, Hummel M, Arauso I, Latza U, Rancso C, Dallenbach F, Stein H. Patterns of cytochine gene expression in infectious mononucleosis. Blood. 1994;83:707–12.
    1. Babcock GJ, Deckler LL, Freema RB, Thorley-Lawson DA. Epstein-Barr virus infected resting memory B cell, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med. 1999;190:567–76.
    1. Thorley-Lawson DA, Babcock GJ. A model for persistent infection with Epstein Barr virus: the stealth virus of human B cells. Life Sci. 1999;65:1433–53.
    1. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene trascription during primary infection and in the carrier state. J Virol. 1994;68:7374–85.
    1. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer. 1985;35:35–42.
    1. Takacs M, Segesdi J, Banati F, Koroknai A, Wolf H, Niller HH, Minarovits J. The importance of epigenetic alterations in the development of Epstein-Barr virus-related lymphomas. Med J Hemat Infect Dis. 2009. available at: .
    1. Capello D, Gaidano G. Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesion and antigen stimulation in the pathogenesis of the disease. Med J Hemat Infect Dis. 2009. available at .
    1. Massini G, Siener D, Hohaus S. EBV in Hodgkin lymphoma. Med J Hemat Infect Dis. 2009. available at: .
    1. Sica S, Metafuni E, Bellesi S, Chiusolo P. Epstein-Barr virus related lymphoproliferations after stem cell transplantation. Medit J Hemat Infet Dis. 2009. available at: .
    1. Kennedy-Messer AA, Bollard CM, Hescop HE. Immunotherapy for Epstein-Barr virus-related lymphomas. Med J Hemat Infect Dis. 2009. available at: .
    1. Contratto AW. Infectious mononucleosis: a study of one hundred and ninety-six cases. Arch Intern Med. 1945;73:449–59.
    1. Milne J. Infectious mononucleosis. N Engl J Med. 1945;233:727–31.
    1. Thompson DS, Godleski J, Herman S. Prognosis post-infectious mononucleosis. J Am Coll Health Assoc. 1969;17:453–7.
    1. Isaacs R. Chronic infectious mononucleosis. Blood. 1948;3:858–61.
    1. Tobi M, Morag A, Ravid Z, Chowers I, Feldman-Weiss V, Michaeli Y, Ben-Chetrit E, Shalit M, Knobler H. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection. Lancet. 1982;1:61–4.
    1. DuBois RE, Seeley JK, Brus I, Sakamoto K, Ballow M, Harada S, Thomas A, Bechtold BA, Pearson G, Purtilo DJ. Chronic mononucleosis syndrome. South Med J. 1984;77:1376–82.
    1. Jones JF, Ray CE, Minnich LL, Hicks MJ, Kible R, Lucas DO. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Int Med. 1985;102:1–7.
    1. Straus SE, Tosato G, Armstrong E, Lawley T, Preble OJ, Henle W, Dvey R, Pearson G, Epstein J, Brus I, Blaese RM. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Int Med. 1985;102:7–16.
    1. Tobi M, Straus SE. Chronic Epstein-Barr virus disease: a workshop held by the National Institute of Allergy and Infectious Diseases. Ann Int Med. 1985;103:951–3.
    1. Holmes GP, Kaplan JE, Stewart JA, Hunt B, Pinsky PF, Schonberger LB. A cluster of patients with chronic mononucleosis-like syndrome: is Epstein-Barr virus the cause? JAMA. 1987;257:2297–302.
    1. Straus SE. The chronic mononucleosis syndrome. J Inf Dis. 1988;157:405–12.
    1. Rickinson AB. Chronic symptomatic Epstein-Barr virus infection. Immunol Today. 1986;7:13–4.
    1. Hellman D, Cowan MJ, Ammann AJ, Wara DW, Chudwin D, Chang RS. Chronic active Epstein-Barr virus infections in two immunodeficient patients. J Pediatr. 1983;103:585–8.
    1. Virelizier JL, Lenoir G, Gricelli C. Persistent Epstein-Barr virus infection in a child with hypergammaglobulinemia and immunoblastic proliferation associated with a selective defect in immune interferon secretion. Lancet. 1978;ii:231–4.
    1. Joncas JH, Ghibu F, Blagdon M, Montplaisir S, Stefanescu I, Menezes J. A familial syndrome of susceptibility to chronic active Epstein-Barr virus infection. Can Med Assoc J. 1984;130:280–4.
    1. Okano M, Matsumoto S, Osato T, Sakiyama Y, Thiele GM, Purtilo DT. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microb Rev. 1991;4:129–35.
    1. Kikuta H, Taguchi K, Tomizawa K, Kojima K, Kawamura N, Ishizaka A, Sakiyama Y, Matsumoto S, Imai S, Kinoshita T, Koizumi S, Osajo T, Kobayashi I, Hamada I, Hirai K. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature. 1988;333:455–7.
    1. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, Matsuyama T, Morishima T. Quantitative analysis of Epstein-Barr virus load by using a realtime PCR assay. J Clin Microbiol. 1999;37:132–6.
    1. Maeda A, Wakiguchi H, Yokoyama W, Hisakawa H, Tomoda T, Kurashige T. Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection. J Infect Dis. 1999;179:1012–5.
    1. Maurmann S, Fricke L, Wagner HJ, Schlenke P, Henning H, Steinoff J, Jabs WJ. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol. 2003;4:5419–28.
    1. Schooley RT. Chronic fatigue syndrome: a manifestation of Epstein-Barr virus infection? Curr Clin Top Infect Dis. 1988;9:126–46.
    1. Kawa-HA K, Ishihara S, Ninomiya T, Yamura-Yagi K, Hara J, Murayama F, Tawa A, Hirai K. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest. 1989;84:51–5.
    1. Ohga S, Takada H, Honda K, Inamura T, Gondo K, Ohshima K, Yamamoto M, Hara T. Central Nervous System T cell lymphoproliferative disorder in a patient with chronic active Epstein-Barr virus infection. J Pediatr Hematol Oncol. 1999;21:42–6.
    1. Kimura H, Hoshino Y, Kanegane H, Tsuge T, Okamura T, Kawa K, Morishima T. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280–6.
    1. Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, Imai S, Okano M, Morio T, Yokota S, Tsuchiya S, Yachie A, Imashuku S, Kawa K, Wakiguchi H, Japanese Association for Research on Epstein-Barr virus and Related Disease Prognostic factors for chronic active Epstein-barr virus infection. J Infect Dis. 2003;187:527–33.
    1. Ishihara S, Okada S, Wakiguchi H, Kurashige T, Morishima T, Kawa-Ha K. Chronic active Epstein-Barr virus infection in children in Japan. Acta Pediatr. 1995;84:1271–5.
    1. Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, Maedda A, Imai S, Ohga S, Kanegane H, Tsuchiya S, Morio T, Mori M, Yokota S, Imashuku S. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hemat. 2005;80:64–9.
    1. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder or immunodeficiency? Rev Med Virol. 2006;16:251–61.
    1. Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee S, Peh S, Chan JKC, the CAEBV Study Group Proposed categorization of pathological states of EBV-associated T natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int. 2008;58:209–17.
    1. Okano M. Overview and problematic standpoints of severe chronic active Epstein-Barr virus infection syndrome. Crit Rev in Oncol Hematol. 2002;44:273–82.
    1. Ishihara S, Ohshima K, Tokura Y, Yabuta R, Imaishi H, Wakiguchi H, Kurashige T, Kishimoto H, Katayama I, Okada S, Kawa-Ha K. Hypersensitivity to mosquito bites conceals clonal lymphoproliferation of Epstein-Barr viral DNA-positive natural killer cells. Jpn J Cancer Res. 1997;88:82–7.
    1. Iwatsuki K, Xu Z, Takata M, Iguchi M, Ohtsuka M, Akiba H, Mitsuhashi Y, Takenoshita H, Sugiuchi R, Tagami H, Kaneko F. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol. 1999;140:715–21.
    1. Kanegane H, Wakiguchi H, Kanegane C, Kurashige T, Miyawaki T, Tosato G. Increased cell-free viral DNA in fatal cases of chronic active Epstein-Barr virus infection. Clin Inf Dis. 1999;28:906–9.
    1. Jones JF, Shurin S, Abramowsky C, Tubbs RR, Sciotto CG, Wahl F, Sands J, Gottman D, Katz BZ, Sklar J. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988;318:733–41.
    1. Kanegane H, Bhatia K, Gutierrez M, Kaneda H, Wada T, Yachie A, Seki H, Arai T, Kagimoto S, Okazaki M, Oh-ishi T, Moghaddam A, Wang F, Tosato G. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood. 1988;91:2085–91.
    1. Imai S, Sugiura M, Oikawa O, Koizumi S, Hirao M, Kimura H, Hayashibara H, Terai N, Tsutumi H, Oda T, Chiba S, Osato T. Epstein-Barr virus (EBV) – carrying and –expressing T cell lines established from severe chronic active EBV infection. Blood. 1996;87:1446–57.
    1. Quintamilla–Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, Sorbara L, Raffeld M, Straus SE, Jaffe ES. Fulminant EBV positive T cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood. 2000;96:443–51.
    1. Lu G, Xie Z, Zhao S, Ye L, Wu R, Liu C, Yang S, Jin Y, Shen K. Clinical analysis and follow-up study of chronic active Epstein-Barr virus infection in 53 pediatric cases. Chin Med J. 122:262–6.
    1. Gartner B, Preiksaitis JK. EBV viral load detection in clinical virology. J Clin Virol. 2010;48:82–90.
    1. Straus SE. History of chronic fatigue syndrome. Rev Infect Dis. 1991;13(Suppl 1):S2–7.
    1. Evans AC. Brucellosis in the United States. Ann J Public Health. 1947;37:139–51.
    1. Holmes GP, Kaplan JE, Gantz NM, Komaroff Al, Schonberger LB, Straus SE, Jones JF, Dubois RE, Cunningham-Rundles C, Pathwa S. Chronic fatigue syndrome: a working case definition. Ann Int Med. 1988;108:387–9.
    1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dubbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Int Med. 1994;121:953–9.
    1. Reyes M, Gary HE, Dobbins JG, Randall B, Steele L, Fukuda K, Holmes GP, Connel DG, Mawle HC, Schimd S, Stewart JA, Schonberger LB, Gunn WJ, Reeves WC. Surveillance for chronic fatigue syndrome-four US cities, september 1989 through august 1993. Surveill Summ. 1997;46:1–13.
    1. Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A, Edwards RH, Hawton KE, Lambert HP, Lane RJ. A report - chronic fatigue syndrome: guidelines for research. J R Soc Med. 1991;84:118–21.
    1. Lloyd AR, Hickie I, Boughton CR, Spencer O, Wakefield D. Prevalence of chronic fatigue syndrome in Australian population. Med J Aust. 1990;153:522–8.
    1. Komaroff AL, Buchwald D. Symptoms and signs in chronic fatigue syndrome. Rev Infect Dis. 1991;13(Suppl):S8–11.
    1. Klonoff DC. Chronic fatigue syndrome. Clin Inf Dis. 1992;15:812–23.
    1. Bombardier CH, Buchwald D. Outcome and prognosis of patients with chronic fatigue vs chronic fatigue syndrome. Arch Int Med. 1995;155:2105–10.
    1. Shafran SD. The chronic fatigue syndrome. Am J Med. 1991;90:730–9.
    1. Salit IE. Precipitating factors for the chronic fatigue syndrome. J Psychiatr Res. 1997;31:59–65.
    1. Levine PH. Epidemiologic advances in chronic fatigue syndrome. J Psychiatr Res. 1997;31:7–18.
    1. Arpino C, Carmen MP, Valesini G, Pizzigallo E, Rovere P, Tirelli U, Conti F, Dialmi P, Barberio A, Rusconi N, Bosco O, Lazzarin A, Saracco A, Moro ML, Vlahov D. Idiopathic chronic fatigue syndrome: a comparison of two case-definitions. Ann Ist Super Sanita. 1999;35:435–41.
    1. Carruthers BM, Jain AK, De Meirleir L, Peterson L, Klimas NG, Lerner AM, Bested AC, Henry PF, Joshi P, Powles P, Sherkey JA, van de Sande MI. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr. 2003;11:7–115.
    1. Vance S, Abbott N. ME/CFS: a research and clinical conundrum. ME/CFS Biomedical Research “New Horizons 2008”, Wellcome Trust Conference Centre Hinxton; Cambridge (UK). 6th may 2008.
    1. Krupp LB, Mendelson WB, Friedman R. An overview of chronic fatigue syndrome. J Clin Psichiatry. 1991;52:403–10.
    1. Keller RH, Lane JL, Klimas N, Reiter WM, Fletcher MA, van Riel F, Morgan R. Association between HLA class II antigens and the chronic fatigue immune dysfunction. Clin Inf Dis. 1994;18(suppl 1):5154–7.
    1. Racciatti D, Barberio A, Vecchiet J, Pizzigallo E. Clinical and pathogenetical characterization of 238 patients of a Chronic Fatigue Syndrome Italian Center. J Chronic Fatigue Syndr. 1998;5:61–70.
    1. Pizzigallo E, Racciatti D, Vecchiet J. Clinical and pathophysiological aspects of chronic fatigue syndrome. J Musculoskeletal Pain. 1999;7:217–24.
    1. Lloyd AR, Hickie I, Loblay RH. Illness or disease? The case of chronic fatigue syndrome. Med J Austr. 2000;172:471–2.
    1. Pizzigallo E, Vecchiet J, Racciatti D. Sindrome da fatica cronica post-virale. “L’impegno di una vita. Scritti in onore di Luigi Ortona”. In: Cauda R, editor. Milano: Vita e Pensiero Edizioni; 2003. pp. 35–70.
    1. Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, Peterson D, Komaroff AL, Ritz S. Phenotipic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987;139:3306–13.
    1. Klimas NG, Salvado F, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28:1403–10.
    1. Demitrack MA, Dale JK, Straus SE, Laue L, Lstwak SJ, Kruesi MJ, Chrousos GP, Gold PW. Evidence for impaired activation of the hypotalamic pituitary adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab. 1991;73:1224–34.
    1. Gillespie NL, Lewis RJ, Pearn JH. Ciguatera in Australia: occurrence, clinical features, pathophysiology and management. Med J Aust. 1986;145:584–90.
    1. Behan PO. Chronic fatigue syndrome as a delayed reaction to chronic low-dose organophosphate exposure. J Nutr Med. 1996;6:341–50.
    1. Pearn JH. Chronic ciguatera: one cause of the chronic fatigue syndrome. J Chronic Fatigue Syndr. 1996;2:29–34.
    1. Wessely S, Chalder T, Hirsch S, Pawlikowska J, Wallace P, Wright DM. Post-infectious fatigue: prospective cohort study in primary case. Lancet. 1995;345:1333–8.
    1. Sigurdsson B, Sigurjonsson J, Sigurdsson JH, Thorkelsson J, Gudmundsson KR. Disease epidemic in Iceland simulating poliomyelitis. Am J Hyg. 1950;52:222.
    1. Poskanzer DC, Henderson DA, Kunkle EC, Kalter SS, Clement WB, Bond JO. Epidemic neuromyasthenia: an outbreak in Punta Gorda, Florida. N Engl J Med. 1957;257:356–64.
    1. Acheson ED. The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyastenia. Am J Med. 1959;4:569–95.
    1. Henderson DA, Shelokov A. Epidemic neuromyasthenia – clinical syndrome? N Engl J Med. 1959;260:757–64.
    1. Barnes DM. Mystery disease at Lake Tahoe challenges virologists and clinicians. Science. 1986;234:541–2.
    1. Buchwald D, Cheney PR, Peterson DL, Henry B, Wormsley SB, Geiger A, Ablashi DV, Salahuddin SZ, Saxinger C, Biddle R, Kikinis R, Jolesz FA, Folks T, Balachandran N, Peter JB, Gallo RC, Komaroff AL. A chronic illness characterized by fatigue, neurologic and immunologic disorders and active human herpes virus type 6 infection. Ann Intern Med. 1992;116:103–13.
    1. Di Luca D, Zorzenon M, Mirandola P, Colle R, Botta GA, Cassai E. Human herpesvirus 6 and human herpesvirus 7 in chronic fatigue syndrome. J Clin Microbiol. 1995;33:1660–1.
    1. Chapenko S, Krumina A, Kozireva S, Nora Z, Sulkanova A, Viksna L, Murdovska M. Activation of human herpes virus 6 an 7 in patients with chronic fatigue syndrome. J Clin Viral. 2006;37(suppl 1):547–51.
    1. Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, Reeves WC, Lloyd A, Dubbo Infection Outcomes Study Group Post-infective and chronic fatifue syndromes precipitated by viral and viral pathogens: prospective cohort study. Br Med J. 2006;333:575.
    1. White PD, Thomas JM, Kangro HO, Bruce-Jones WD, Amess J, Crawford DH, Grover SA, Clare AW. Predictions and associations of fatigue syndrome and mood disorders that occur after infectious mononucleosis. Lancet. 2001;358:1946–54.
    1. Dowsett EG, Ramsay AM, McCartney RA, Bell EJ. Myalgic encephalomyelitis - a persistent enteroviral infection? Postgrad Med J. 1990;66:526–30.
    1. Gow JW, Behan WM, Simpson K, McGarry F, Keir S, Behan PO. Studies on enterovirus in patients with chronic fatigue syndrome. Clin Infect Dis. 1994;18(suppl 1):5126–9.
    1. Chia JK, Chia AY. Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J Clin Pathol. 2008;61:43–8.
    1. Maes M, Mihaylova I, Leunis JC. Increased serum IgA and IgM against LPS of enterobacteria higher in chronic fatigue syndrome (CFS): indication for involvement of gram-negative bacteria in the etiology of CFS and the presence of an increased gut-intestinal permeability. J Affect Disord. 2007;99:237–40.
    1. Lombardi V, Ruscetti F, Gupta J, Pfost K, Peterson D, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science. 2009;326:585–9.
    1. van Kuppeveld F, de Jong A, Lanke K, Verhaegh GW, Melchers WJ, Swanink CM, Bleijenberg G, Netea MG, Galama JM, van Der Meer JW. Prevalence of xenotropic murine leukemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. Br Med J. 2010;340:c1018.
    1. Erlwein O, Kaye S, McClure MO, Weber J, Willis G, Collier D, Wesseley S, Cleare A. Failure to detect the novel XMRV in chronic fatigue syndrome. PLoS One. 2010;5:e8519.
    1. Groom H, Boucherit V, Makinson K, Randal E, Baptista S, Hagan S, Gow JW, Mattes FM, Breuer J, Kerr JR, Stoye JP, Bishop KN. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology. 2010;15:7–10.
    1. Pall ML. Elevated, sustained peroxydative levels as the cause of chronic fatigue syndrome. Med Hipotheses. 2000;54:115–25.
    1. Fulle S, Mecocci P, Fanò G, Vecchiet J, Vecchini A, Racciatti D, Cherubini A, Pizzigallo E. Vecchiet L, Senin U, Beal MF. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med. 2000;29:1252–9.
    1. Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HL. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep. 2000;5:35–41.
    1. Vecchiet J, Cipollone F, Falasca K, Mezzetti A, Pizzigallo E, Bucciarelli T, De Laurentis S, Affaitati G, De Cesare D, Giamberardino MA. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett. 2003;335:151–4.
    1. Behan PO, Behan WM, Horrobin D. Effects of high doses of essential fatty acids on the post-viral fatigue syndrome. Acta Neurol Scand. 1990;82:209–16.
    1. Pall ML. Levels of nitric oxidative synthase product citrulline are elevated in sera of CFS patients. J Chronic Fatigue Syndr. 2002;10:34–41.
    1. Smirnova IV, Pall ML. Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. Mol Cell Biochem. 2003;248:93–5.
    1. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med. 2005;39:584–9.
    1. Jammes Y, Steinberg JG, Mambrini O, Bregeon F, Delliaux S. CFS: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern med. 2005;257:299–310.
    1. Miwa K, Fujita M. Increased oxidative stress suggested by low serum vitamin E concentrations in patients with chronic fatigue syndrome. Int J Cardiol. 2009;136:238–9.
    1. Klimas NG, O’Brien Koneru A. Chronic fatigue syndrome: inflammation, immune function and neuroendocrine interactions. Curr Rheumatol Rep. 2007;9:482–7.
    1. Vernon SD, Whistler T, Cameron B, Hickie IB, Reeves WC, Lloyd A. Preliminary evidence of mithocondrial dysfunction associated with post-infective fatigue after acute infection with Epstein-Barr virus. BMC Infect Dis. 2006;6:15.
    1. White NJ, Jvel-Jensen BE. Infectious mononucleosis hepatitis. Semin Liver Dis. 1984;4:301–6.
    1. Hinedi TB, Koff RS. Cholestatic hepatitis induced by Epstein-Barr virus infection in an adult. Dig Dis Sci. 2003:539–41.
    1. Shaukat A, Tsai HT, Rutherford R, Anania FA. Epstein-Barr virus induced hepatitis: an important cause of cholestasis. Hepatol Res. 2005;33:24–6.
    1. Markin RS, Linder J, Zuerlein K, Mroczek E, Grierson HL, Brichacek B, Purtilo DT. Hepatitis in fatal infectious mononucleosis. Gastroenterology. 1987;93:1210–7.
    1. Cacopardo B, Nunnari G, Mughini MJ, Tosto S, Benanti F, Nigro L. Fatal hepatitis during Epstein-Barr virus reactivation. Eur Rev Med Pharmacol Sci. 2003;7:107–9.
    1. Chiba T, Goto S, Yokosuka O, Imazeki F, Tanaka M, Fukai K, Takahashi Y, Tsujimura H, Saisho H. Fatal chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2004;16:225–8.
    1. Vento S, Cainelli F. Is there a role for viruses in triggering autoimmune hepatitis? Autoimmune Rev. 2004;3:61–9.
    1. Biest S, Schubert TT. Chronic Epstein-Barr virus infection: a cause of granulomatous hepatitis. J Clin Gastroenterol. 1989;11:343–6.
    1. Negro F. The paradox of Epstein-Barr virus associated hepatitis. J Hepatol. 2006;44:839–41.
    1. Sakamoto T, Vemura M, Fukui H, Yoshikawa M, Fukui K, Kinoshita K, Kojima H, Matsumori T, Tsujii T, Sumakari R. Chronic active Epstein-Barr virus infection in an adult. Intern Med. 1992;31:1190–6.
    1. Yuge A, Kinoshita E, Moriuchi M, Ohno Y, Haga H, Moriuchi H. Persistent hepatitis associated with chronic active Epstein-Barr virus infection. Pediatr Infect Dis J. 2004;23:74–6.
    1. Drebber U, Kasper HU, Krupacz J, Hferkamp K, Kern MA, Steffen HM, Quasdurff M, zur Hausen A, Odenthal M, Dienes HP. The role of Epstein-Barr virus in acute and chronic hepatitis. J Hepatol. 2006;44:879–85.
    1. Petrova M, Muhtarova M, Nikolova M, Magaev S, Taskov H, Nikolovska D, Krastev Z. Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients. World J Gastroenterol. 2006;12:5711–6.
    1. Li W, Wu BA, Zeng Y. Epstein-Barr virus in hepatocellular carcinogenesis. World J Gastroenterol. 2004;10:3409–13.
    1. Kamei S, Takasu T. Nationwide survey of the annual prevalence of viral and other neurological infections in Japanese inpatients. Intern Med. 2000;39:894–900.
    1. Neumann B, Ritter K, Prange HW. Encephalitis in association with chronic active Epstein-Barr virus infection. J Neuroimmunol. 1988;20:169–70.
    1. Adachi W, Iwasaki S, Tuji T, Hamaguchi K, Katayama I. A case of meningoencephalitis caused by persistent Epstein-Barr virus infection. Rinsho Shinkeigaku. 1989;29:89–92.
    1. Fujimoto H, Asaoka K, Imaizumi T, Ayabe M, Shoji H, Kaji M. Epstein-Barr virus infections of the Central Nervous System. Intern Med. 2003;42:33–40.
    1. Vladutin GD, Natelson BH. Association of medically unexplained fatigue with ACE insertion/deletion polymorphism in Gulf War veterans. Muscle Nerve. 2004;30:38–43.
    1. Kaushik N, Fear D, Richards SC, McDermott CR, Nuwaysir EF, Kellar P, Harrison TJ, Wilkinson RJ, Tyrrell DA, Holgate ST, Kerr JR. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol. 2005;58:826–32.
    1. Carlo-Stella N, Badulli C, De Silvestri A, Bazzicchi L, Martinetti M, Lorusso L, Bombardieri S, Salvaneschi L, Cuccia M. A first cytokine polymorphism in CFS: positive association of TNF-857 and IFN-gamma 874 rare alleles. Clin Exp Rheumatol. 2006;24:179–82.
    1. Whistler T, Taylor R, Craddock RC, Broderick G, Klimas N, Unger ER. Gene expression correlates of unexplained fatigue. Pharmacogenomics. 2006;7:395–405.
    1. Fang H, Xie Q, Buneva R, Fostel J, Perkins R, Tong W. Gene expression profile exploration of a large dataset on chronic fatigue syndrome. Pharmacogenomics. 2006;7:429–40.
    1. Rajeevan MS, Smith AK, Dimulescu I, Unger ER, Vernon SD, Heim C, Reeves WC. Glucocorticoid receptor polymorphism and haplotypes associated with chronic fatigue syndrome. Genes Brain Behav. 2007;6:76. 167:
    1. Saiki T, Kawai T, Morita K, Ohta M, Saito T, Rokutan K, Ban N. Identification of marker genes for differential diagnosis of chronic fatigue syndrome. Mol Med. 2008;14:599–607.
    1. Aspler AL, Bolshin C, Vernon SD, Broderick G. Evidence of inflammatory immune signaling in chronic fatigue syndrome: a pilot study of gene expression in peripheral blood. Behav Brain Funct. 2008;26:4–44.
    1. Kerr JR, Burke B, Petty R, Gough J, Fear D, Mattey DL, Axford JS, Dalgleish AG, Nutt DJ. Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pat. 2008;61:730–9.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe